Seattle Allergy & Asthma Research Institute

Seattle Allergy & Asthma Research Institute, previously ASTHMA Inc. Clinical Research Center, was founded in 1972 by two physicians from Northwest Asthma & Allergy Center (NAAC) who wanted to advance investigation and treatments in allergy, asthma and immunology.

Today, the institute is comprised of a broad team of dedicated allergy and immunology specialists, nurses and research coordinators all working together as a cohesive team to conduct clinical allergy research in the Seattle area. All Institute’s physicians are affiliated with University of Washington School of Medicine and Seattle Children’s Hospital and we have an active partnership with both these institutions.

To this day, we honor our original mission: to conduct high quality research to improve understanding and treatment of allergies, asthma and other diseases for patients everywhere.

We are proud to be the go-to research facility for the research and development divisions of major pharmaceutical companies as well as numerous high profile organizations, including the National Heart Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID). We support them with careful medical research and have completed more than 500 FDA-approved clinical trials to date.

A FEW REASONS OUR PARTNERS & STUDY CANDIDATES LOVE WORKING WITH US:

  • Unparalleled experience. With over 500 clinical research studies to our credit, we have studied adult and pediatric populations across several areas of study including food allergy, asthma, sinusitis, influenza, seasonal allergic rhinitis, perennial allergic rhinitis, and more.

  • FARE: Food Allergy Center of Excellence. We are proud to be one of a small group of certified food allergy centers of excellence in the country.

  • Professionals at the top of their game. Our investigators are clinicians who deliver accuracy, quality and expertise in research, and have done so for both corporations and government organizations

  • An interdisciplinary approach. We bring together clinical, scientific, regulatory, industry and business expertise on each project, to ensure the highest quality of research and service.

  • A dedicated non-profit. Our 30% indirect cost rate is competitive with academic research centers, and reflects our flexible, non-profit business structure

  • Full circle testing support. Our ability to conduct Phase 1, 2, 3 and post-marketing studies

  • A research center. We serve as a site for clinical research training and education.

  • Strong patient recruitment. We have a strong database of and outreach to interested subjects and continuously recruit and screen study candidates.

  • Monitoring and support. We provide ongoing education for potential/enrolled subjects and strictly monitor subject participation.

  • State of the art technology. From equipment to the technology we use, our studies benefit from best-in-class options.

  • Confidentiality. Our sponsors know they can rely on us to provide accurate data in a timely fashion, and discreetly.

IN PARTNERSHIP WITH

Northwest Asthma and Allergy
Seattle Childrens
University of Washington
SeaFac

EXECUTIVE DIRECTOR
DR. DANIEL PETRONI

Dr. Petroni is the Executive Director of Seattle Allergy & Asthma Research Institute and Principal Investigator on all of our studies. He brings clinical and research expertise together, holding both an MD and PhD in Pharmacology from Tulane University School of Medicine. He completed his internship and residency in Pediatrics at the University of California Davis Medical Center, followed by an Allergy and Immunology fellowship at the University of Washington. Dr. Petroni has a special research interests in the field of food allergy and immunodeficiency.

SAMPLING OF RECENT PUBLICATIONS
Petroni DH, et. al Approach to the Evaluation of Adverse Antibiotic Reactions In Cystic Fibrosis Patients. Ann Allergy Asthma Immunol.Epub 2016 Aug 31. PMID: 27590641
Ochs HD, Petroni D. From clinical observations and molecular dissection to novel therapeutic strategies for primary immunodeficiency disorders. Am J Med Genet A. 2017 Sep 21.
Sun A, Alshuaibi W, Petroni D, Skoda-Smith S, Goldberg MJ, Hale S. Immune modulation in a patient with Morquio syndrome treated with enzyme replacement therapy.J Allergy Clin Immunol Pract. 2018 Feb 6
Petroni D, Spergel JM. Eosinophilic esophagitis and symptoms possibly related to eosinophilic esophagitis in oral immunotherapy. Ann Allergy Asthma Immunol. 2018 Jan 31.
Tilles SA, Petroni D. FDA-approved peanut allergy treatment: The first wave is about to crest. Ann Allergy Asthma Immunol. 2018 Aug
Constantine GM, Bressler PB, Petroni D, Metcalfe DD, Carter MC. Twelve-year follow-up of omalizumab therapy for anaphylaxis in 2 patients with systemic mastocytosis. J Allergy Clin Immunol Pract. 2018 Aug 24.

SUB-INVESTIGATOR
DR. LISA WINTERROTH

Dr. Winterroth is a Seattle native who received her medical degree from Albert Einstein College of Medicine in New York in 2009. She then completed a residency in Pediatrics at Stanford University before returning to Seattle to complete a fellowship in Allergy & Immunology at the University of Washington. Dr. Winterroth became interested in clinical research during her residency at Stanford when she assisted in several clinical trials examining the use of oral immunotherapy for the treatment of food allergies. While at Stanford, she co-authored one of the first manuscripts examining the safety of oral immunotherapy using multiple food allergens simultaneously. During her fellowship at the University of Washington, she served as sub-investigator on several clinical trials through ASTHMA Inc. She currently divides her time between serving as a sub-investigator at ASTHMA Inc. and seeing patients at Northwest Asthma & Allergy Center. She is board-certified in both Pediatrics and Allergy & Immunology and has a special interest in food allergies.

SAMPLING OF RECENT PUBLICATIONS
Winterroth LC, Williams, PV. Consequences of antibiotics and infections in infancy: bugs, drugs, and wheezing. Pediatrics. 2014
Winterroth LC, Williams, PV. Efficacy and Safety of Grass Sublingual Immunotherapy Tablet, MK-7243: A Large Randomized Controlled Trial. Pediatrics.
Begin P, Winterroth LC, Dominguez T, Wilson SP, Bacal L, Mehrotra A, Kausch B, Trela A, Hoyte E, O’Riordan G, Seki S, Blakemore A, Woch M, Hamilton RG, Nadeau KC. Safety and feasibility of oral immunotherapy to multiple allergens for food allergy. Allergy, Asthma, & Clinical Immunology. 2014 Jan 15;10(1):1.
Liu J, Zhang L, Winterroth LC, Garcia M, Weiman S, Wong JW, Sunwoo JB, Nadeau KC. Epigenetically mediated pathogenic effects of phenanthrene on regulatory T cells. Journal of Toxicology.

OTHER SUB-INVESTIGATORS

Andrew G. Ayars, MD   •   Leonard C. Altman, MD  •   Mary V. Lasley, MD

Sara P. Seghezzo, MD  •   Ashley Jerath Tatum, MD  •   Frank S. Virant, MD

STAFF

Lisa Miller, CCRC – Clinical Research Manager

Allison Kunze, BS – Assistant Research Medical Assistant

Robin Kintner, BA, CCRC – Regulatory Coordinator

Joy Fernandez, CMA– Research Medical Assistant Lead

Tara Derovanessian, BS – Clinical Research Coordinator

Marissa Nelsen, BS – Clinical Research Coordinator